Invus recognizes that every company is unique and that extraordinary business performance cannot be achieved by following a formulaic approach. Due to their unique structure, they have a great deal of flexibility in the types of companies and situations where they can get involved.

Perhaps most importantly, they know that real transformation takes time and that itâ€™s never a straight line. They fully align their incentives with their partners and have the wherewithal and long-term commitment to see through any bumps along the way.

They have been successfully empowering owner-managers since 1985. They have been reinvesting the same pool of money from the same group of European families (through their Artal investment vehicle) since their founding. Today they manage over $4 billion in an evergreen fund and work out of offices in New York, London, Paris and Hong Kong.

The Invus Group

President and CEO

MD, Private Equity

Director, Private Equity

Vigil Neuroscience raised $90000000 on 2021-08-18 in Series B

Vigil will use the Series A funds to progress its lead pipeline candidate, a monoclonal antibody TREM2 agonist, through Phase 1 studies, advance their small molecule TREM2 agonist to IND, as well as pursue additional assets to grow the pipeline and increase the body of data supporting microglia biology as an important therapeutic pathway.

Vigil Neuroscience

Arcus Biosciences raised $70000000 on 2016-09-01 in Series B

Arcus Biosciences is biotech company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. Arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the San Francisco bay area, in the heart of the world’s largest biotechnology research hub.

Arcus Biosciences, Inc.

Ambrx raised $200000000 on 2020-11-09 in Private Equity Round

Ambrx is a biopharmaceutical company that develops protein therapeutics that preserve potency, reduce dosing frequency, and improve homogeneity of the drug substance. It focuses on discovering and developing biopharmaceutical products. 

Ambrx's development pipeline includes ADC and bi-specific product candidates, long-acting protein product candidates, collaboration product and product candidates, and other early-stage programs. It has collaborations with MabSpace Biosciences to discover and develop various antibody drug conjugates for oncology in China and internationally; and BeiGene to develop and commercialize next-generation biologics drugs. 

Peter Schultz and Troy Wilson founded Ambrx in 2003. It has its headquarters in La Jolla in California.

Ambrx, Inc.

Zenflow raised $31400000 on 2018-02-07 in Series A

Zenflow, Inc. develops and markets a spring device that provides relief for permanent BPH symptoms in men. The company provides solutions for urinary obstruction without destroying tissues. It offers its products for patients and urologists. The company was formerly known as Torix Medical, Inc. The company was founded in 2014 and is based in San Francisco, California.

Zenflow, Inc.

Dropee raised $66874 on 2017-01-01 in Pre Seed Round

Dropee is a SaaS-enabled marketplace that connects local independent retailers with brands in South East Asia via an ordering app. The marketplace's unique value proposition makes it easier for businesses both big and small to manage their procurement and supply chain ecosystem. It allows businesses to get connected in order to buy and sell in bulk and the enterprise solution allows businesses to streamline their operational processes to work more efficiently and effectively.

Dropeee’s platform connects suppliers with small-to-medium enterprise (SME) business owners in real-time to streamline the product fulfillment process and facilitate bulk purchases through a suite of enterprise solutions. The supply-chain in Malaysia and across Southeast Asia lacks meaningful real-time connectivity between suppliers and retailers. The modern, digital approach to the wholesale industry allows retailers to discover, purchase, and manage inventories for their store all on a single marketplace platform.

Dropee.com

The Curious AI Company raised $3670000 on 2017-09-23 in Venture Round

Deep good. Unsupervised better. The Curious AI Company is making the digital co-workers of the future.

The Curious AI Company develops artificial general intelligence (AI). The company focuses on autonomous and interactive machine learning technologies. Building on more than two decades of work in bio-inspired AI by founder Harri Valpola, PhD, Curious AI delivers industrial pilot projects while building a long-term, complete AI deep tech portfolio.

Curious AI Oy

Health Data Analytics Institute raised $16000000 on 2020-03-03 in Venture Round

Health Data Analytics Institute is created a predictive platform that transcends the understanding of healthcare data and connects it to quantifiable, actionable information that benefits patients, providers, and society. But we don’t just translate data, we transform it into a continuum of insights — applicable across all touch points in an individual’s dynamic health journey. It’s deep knowledge that quantifies longevity, health status, health risks, and health costs. But that’s just the start.

Health Data Analytics Institute

BioNTech raised $325000000 on 2019-07-09 in Series B

BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline.

BioNTech AG

PrimeraDx (Primera Biosystems) raised $21000000 on 2008-01-09 in Series B

PrimeraDx, Inc. offers multiplexed infectious disease assays. It provides Scalable Target Amplification Routine technology, which is a method for simultaneous quantitative measurement of multiple target nucleic acids. The company also offers ViraQuant, a multiplexed assay providing quantitative and simultaneous measurement of viruses; and FungiQuant Yeast and FungiQuant Mold, which are fungal panels for mycology testing. Its products are used in miRNA, DNA methylation, quantitative genotyping, gene expression, and viral load measurement applications. PrimeraDx, Inc. was founded in 2004 and is based in Mansfield, Massachusetts.

PrimeraDx (Primera Biosystems)

Future Finance raised $29179022 on 2016-03-14 in Series B

Future Finance is a non-government lender that offers student loans.

Its mission is to provide loans for students that are simple, straightforward, and based on where they're heading, not where they've been. Future Finance helps students focus on what matters. Therefore, it aims to ensure everyone has the freedom to focus on their studies or kickstart their career whatever their financial background may be. 

It was founded in 2014 by Brian Norton and Vishal Garg and is headquartered in Dublin.

Future Finance

Enwise raised $20000000 on 2020-03-16 in Angel Round

Enwise

Lexicon Pharmaceuticals raised $75040000 on 2010-03-15 in Post-IPO Equity

Lexicon Pharmaceuticals, Inc. (formerly Lexicon Genetic) a biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of human disease, including immunology, metabolism, cardiology, and ophthalmology. The company's drug candidates include LX1031, which has completed Phase II clinical trials for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX4211 that has completed Phase II clinical trials to treat type 2 diabetes; LX2931, which is in Phase II clinical trials for the treatment of rheumatoid arthritis and other autoimmune diseases; and LX1032 that has completed Phase II clinical trials to treat the symptoms associated with carcinoid syndrome. It also has a preclinical development drug candidate, LX7101, for the treatment of glaucoma. The company has drug discovery alliances with Bristol-Myers Squibb Company; Genentech, Inc.; N.V. Organon; and Takeda Pharmaceutical Company Limited. It also has drug development financing collaboration with Symphony Icon; collaboration agreement with Taconic Farms, Inc.; and an alliance with Nuevolution A/S, which provides access to Nuevolution's Chemetics platform chemistry technology.

Lexicon Pharmaceuticals, Inc.

Ikena Oncology raised $120000000 on 2021-01-05 in Series B

Ikena Oncology is dedicated to bringing next generation oncology therapies to patients suffering from cancer. Ikena Oncology are committed to leveraging our unique understanding of the complex biologic pathways that drive the formation and spread of cancers to discover and develop novel, patient-directed therapies. Selecting patients for treatment in clinical studies with biomarkers we develop is at the core of our strategy.

Kyn Therapeutics

Foghorn Therapeutics raised $61000000 on 2019-05-12 in Venture Round

Foghorn Therapeutics is developing therapies based on a system that directs which genes our cells express, and when, where, and in what order.By manipulating this system with our unique Gene Traffic ControlTM platform, Foghorn will change how genes turn “on” and “off.” Unlike approaches that edit genes, this novel way of thinking will alter what our DNA has in store for us—and rewrite destiny for millions of people living with disease.With Gene Traffic ControlTM Foghorn is pioneering a new, major class of drug targets to develop unprecedented therapies for cancer and other serious diseases. We have already validated multiple targets, are in the process of developing drug candidates in multiple types of cancer and are beginning to explore other diseases.

Foghorn Therapeutics Inc.

Zero Motorcycles raised $5564220 on 2010-01-05 in Series A

Zero Motorcycles, Inc. manufactures and supplies electric motorcycles. It offers street, dirt, and dual sport motorcycles; and accessories, apparel, fairings and bodywork, parts, tires and wheels, and upgrades. The company sells its products through dealers and online. The company has a strategic partnership with Polaris Inc. Zero Motorcycles, Inc. was formerly known as Electricross, Inc. The company was founded in 2006 and is based in Scotts Valley, California with an additional office in Noord-Scharwoude, the Netherlands.

Zero Motorcycles Inc.

Flare Therapeutics raised $123000000 on 2023-03-22 in Series B

Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets for transcription factor regulation to address mutations that cause disease. Our drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.

Flare Therapeutics

Asher Bio raised $108000000 on 2021-09-01 in Series B

Asher Bio is an information technology company that specializes in the fields of CFO Office transformation, profitability, and cost management. It focuses on building and developing better immunotherapy for cancer.

The company was founded in 2019 and headquartered in San Francisco, California.

Asher Bio

Yumanity Therapeutics raised $33599895 on 2020-12-15 in Venture Round

Yumanity Therapeutics is transforming drug discovery for neurodegenerative diseases caused by protein misfolding. Founded in December 2014 by award-winning protein folding expert, Susan Lindquist, and renowned biotech industry leader, Tony Coles, Yumanity is working to identify and develop new, disease-modifying therapies that address several illnesses with critical unmet medical needs. The initial focus of the company is neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis (ALS). 

The company’s proprietary platforms have already identified one potential new target for treating Parkinson’s disease, and Yumanity is actively advancing its new chemical lead series for this condition, as well as identifying additional compounds for Alzheimer’s disease and ALS.

Yumanity Therapeutics, Inc.

Convergent Therapeutics raised $90000000 on 2023-05-03 in Series A

Convergent Therapeutics

Achilles Therapeutics raised $69813622 on 2020-11-19 in Series C

Achilles Therapeutics is a developer of immunotherapies intended to offer next-generation, patient-specific therapies to treat cancer. The company's immunotherapies harness the immune system to destroy cancer cells that target truncal tumor neo-antigens and flags to the immune system present on the surface of every cancer cell, enabling scientists to target and destroy tumors without harming healthy tissues.

Achilles Therapeutics

MOMA Therapeutics raised $150000000 on 2022-05-10 in Series B

MoMa Therapeutics, Inc. discovers precision medicines by targeting the molecular machines that underlie human disease. MoMa Therapeutics, Inc. was formerly known as ATPases NewCo, Inc. and changed its name to MoMa Therapeutics, Inc. in March 2020. The company was founded in 2019 and is based in Cambridge, Massachusetts.

MOMA Therapeutics

Asher Bio raised $55000000 on 2021-03-23 in Series A

Elixir Medical raised $5299700 on 2005-03-18 in Series A

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, CA, specializes in developing products that combine state-of-the-art medical devices with advanced pharmaceuticals.
The company's next-generation drug-eluting stent systems are designed to optimize localized drug delivery to provide a safe and effective treatment for cardiovascular patients.

Elixir Medical

Jumbotail raised $84914166 on 2021-12-20 in Series C

Jumbotail Technologies Pvt. Ltd. owns and operates an online marketplace for wholesalers to sell their products and services. The company was founded in 2015 and is based in Bengaluru, India.

Jumbotail

Enwise raised an undisclosed amount on 2016-12-01 in Seed Round

Flare Therapeutics raised $82000000 on 2021-05-13 in Series A

Snagajob raised $100000000 on 2016-02-04 in Series D

Snagajob is the platform for hourly work with 100 million registered hourly workers and 470,000 employer locations nationwide. With Snagajob, hourly workers find work more easily and employers staff up faster, hire smarter and keep shifts filled. Snagajob's platform for jobs and shifts allows people to land the right work while ensuring employers find the right workers when and where they need them.

Snagajob was founded in 1999 and is based in Glen Allen, Virginia, United States.

Snag

Ring Therapeutics raised $117000000 on 2021-07-28 in Series B

Ring Therapeutics is a multi-product platform company focused on discovering and developing Anellovector therapeutics to unlock the full potential of gene therapy. Founded by Flagship Pioneering, Ring is pioneering the first redosable and targetable gene therapy platform by harnessing the biology of the human commensal virome. The company is expanding the applications of gene therapy beyond gene replacement, enabling a much wider array of modalities and mechanisms to treat previously inaccessible diseases.

Ring Therapeutics

PrimeraDx (Primera Biosystems) raised $20000000 on 2009-10-30 in Series C

FlatFrog Laboratories raised $18000000 on 2010-01-20 in Venture Round

FlatFrog's mission is to bring to life the exciting new world of multi-touch computing and applications.

Designed from inception for volume production, our patented technologies enable unmatched in-glass multi-touch performance for large and flat displays.

FlatFrog was founded by Ola Wassvik and serial entrepreneur Christer FÃ¥hraeus. The company is privately held with headquarters in Lund, Sweden, near the bridge to Copenhagen, Denmark.

FlatFrog Laboratories AB

Leyden Labs raised $140000000 on 2022-01-25 in Series B

Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains of respiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses.

Leyden Labs

Abound Solar raised $104000000 on 2008-08-29 in Venture Round

Abound Solar produces next-generation, thin film photovoltaic modules intended to deliver the lowest levelized cost of electricity.

Abound Solar

BioNTech raised $270000000 on 2018-01-04 in Series A

Scorpion Therapeutics raised $162000000 on 2021-01-07 in Series B

Scorpion Therapeutics, Inc., a biotechnology company, develops next-generation precision oncology technologies for the treatment of cancer. The company develops precision oncology drugs in three areas, including therapies against known oncogenes; agents for known but currently undruggable cancer targets; and drugs for new targets. Scorpion Therapeutics, Inc. was founded in 2020 and is based in Boston, Massachusetts.

Scorpion Therapeutics, Inc.

Korro Bio raised $116000000 on 2022-01-05 in Series B

Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.

Korro Bio was created to lead the field of RNA editing. The company is advancing a proprietary platform designed to selectively edit messenger RNA and recode specific codons to effect changes in protein structure and function across multiple tissues.

In 2018,

Korro Bio

Thrive Earlier Detection raised $257000000 on 2020-07-29 in Series B

Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. 

It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering.

The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.

Thrive Earlier Detection

Marlette Funding raised $75000000 on 2015-07-21 in Venture Round

Marlette Funding is a financial tech company tasked to empower customers. It specializes in online lending services providing a frictionless application and a fast funding process. It has facilitated over $7B in loans to more than 350,000 people who use the loans to finance large purchases or consolidate and pay off debt.

It was incorporated in 2013 and is based in Wilmington, Delaware.

Marlette Funding, LLC

Senti Biosciences raised $50600000 on 2022-06-09 in Post-IPO Equity

Senti Biosciences is a team of bioengineers, scientists, and entrepreneurs on a mission to treat the most complex and challenging diseases. Led by pioneers in synthetic biology and computation, Senti is using the latest techniques in the fields to build the future of gene and cell-based therapies. Senti’s proprietary synthetic biology platform provides fundamental advantages for therapeutics development. Senti Biosciences is a resident company of Johnson & Johnson Innovation, JLABS at South San Francisco (JLABS @ SSF).

Senti Biosciences, Inc.

Future Finance raised $49572376 on 2018-03-13 in Series C

PACT Pharma raised $95000000 on 2018-05-25 in Series B

Pact Pharma is a developer of personalized adoptive T cell therapies designed for the eradication of solid tumors.The company's therapies help in the identification of neo-epitopes that serve as private mutations for each patient's cancer as well as creates an opportunity to engineer autologous T cells that target and kill tumors expressing these neo-antigens, enabling physicians to recognize and remove each patient's cancer cells.

PACT Pharma, Inc.

Onxeo raised $8718158 on 2022-04-06 in Post-IPO Equity

Onxeo is a biotechnology company that develops drugs for oncology. It offers Beleodaq, a histone deactylase inhibitor for the treatment of peripheral T-cell lymphoma; Livatag, a nanoparticle formulation of doxorubicin, which is in Phase III clinical trials for the treatment of primary liver cancer; Validive, a mucoadhesive buccal tablet that is in Phase II clinical trials for the prevention and the treatment of chemoradioation therapy-induced severe oral mucositis in patients with head and neck cancer; and Combo BelCHOP, which is Phase II clinical trials for the treatment of peripheral T-cell lymphoma.

Onxeo is headquartered in Paris, France.

Onxeo SA

Zero Motorcycles raised $6000000 on 2012-10-01 in Venture Round

HappyVore raised $36912744 on 2022-06-16 in Funding Round

Les Nouveaux Fermiers cultivates a passion for taste, the real, the healthy, and the impact on the planet. It reinvents meat from natural and local plant ingredients to better feed the planet. Its products today represent 11 times less CO2 and 10 times less water than meat production.

It was founded in 2019 and is headquartered in Paris, France.

Les Nouveaux Fermiers

E-Color raised $9000000 on 2000-03-07 in Venture Round

E-Color develops software solutions for color consistency and optimization on the Web. It delivers enhanced images while shopping online, printing digital photos, playing video games, and watching DVD movies. E-Color, Inc. was formerly known as Sonnetech, Ltd.

E-Color

Evox Therapeutics raised $96571704 on 2021-02-18 in Series C

Evox Therapeutics Limited develops a modular platform for clinical translation of exosome-based therapeutics. The company develops extracellular vesicles-based nucleic acid and protein delivery technology. Its technology aims to hitch a ride on tiny particles called exosomes, which the body uses to transport molecules between cells. Evox Therapeutics Limited was founded in 2016 and is based in Oxford, United Kingdom.

Evox Therapeutics Limited

Sagimet Biosciences raised $80000000 on 2021-02-11 in Venture Round

Sagimet Biosciences is a biotechnology company that focuses on developing novel therapeutics to treat important diseases such as liver disease NASH and specific cancers, with a focus on targeting dysfunctional metabolic pathways.

It was founded in 2007 and headquartered in San Mateo, California.

3-V Biosciences

Black Diamond Therapeutics raised $85000000 on 2019-01-09 in Series B

Black Diamond Therapeutics, Inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Its lead product candidate is BDTX-189, an inhibitor of non-canonical and oncogenic mutations of ErbB kinases epidermal growth factor receptor (EGFR) and tyrosine-protein kinase. The company is also developing allosteric-EGFR mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Black Diamond Therapeutics, Inc.

Bright Peak Therapeutics raised $107000000 on 2021-06-10 in Series B

Bright Peak Therapeutics is a biotechnology company with a platform capable of chemically synthesizing and optimizing natural proteins such as cytokines.

Bright Peak Therapeutics

Opera Solutions raised $84000000 on 2011-09-14 in Private Equity Round

Opera Solutions

Hookipa Pharma raised $37400000 on 2019-02-26 in Series D

HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company’s lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.

HOOKIPA Pharma Inc.

Viseon raised $18000000 on 2020-02-25 in Series B

Viseon, Inc. operates as a medical device company. It has developed the Voyant technology for use in both posterior and lateral access MIS spine procedures. The company’s technology offers a single-use disposable alternative to surgical microscopes, endoscopes and loupes, projecting the operative field onto a high definition flat panel display within the OR and to remote locations. Viseon, Inc. was incorporated in 2017 and is based in Irvine, California.

Viseon Spine

Kythera Biopharmaceuticals raised $37400000 on 2011-09-19 in Series D

KYTHERA Biopharmaceuticals, Inc., formerly known as AESTHERx, Inc., was founded in August 2005 and is a privately held biopharmaceutical company located north of Los Angeles in southern California.

KYTHERA is focused on science and innovation in aesthetic medicine. This market is expanding rapidly driven by an aging population, increasing discretionary income, and an evolution of patient preference toward restorative and preventative care. The company uses the tools of biotechnology to develop prescription therapeutics for this emerging market.

Kythera Biopharmaceuticals

The Curious AI Company raised $895330 on 2015-10-01 in Seed Round

ImCheck Therapeutics raised $99985627 on 2022-06-13 in Series C

ImCheck Therapeutics SAS develops immunotherapeutics for patients with severe unmet medical needs. The company primarily focuses on immuno-oncology. It develops immunotherapy antibodies, which include immunomodulators and butyrophilins to treat a range of autoimmune diseases. The company was founded in 2015 and is based in Marseille, France.

ImCheck Therapeutics SAS

Enwise raised an undisclosed amount on 2018-01-01 in Venture Round

Gossamer Bio raised $120000000 on 2022-07-13 in Post-IPO Equity

Gossamer Bio is a San Diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. Founded by the former Receptos executive team, Gossamer Bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

Gossamer Bio, Inc.

AlloVir raised $126600000 on 2022-07-27 in Post-IPO Equity

AlloVir focuses on the development of cell therapies and focuses on restoring natural immunity against the virus-associated diseases. It provides an ideal environment for ViraCyte to develop and advance its product pipeline from discovery through late-stage clinical trials.

The company was founded in 2013 and headquartered in 	Houston, Texas.

ViraCyte

Zero Motorcycles raised $2200000 on 2012-01-01 in Venture Round

Scholar Rock raised $205000000 on 2022-06-17 in Post-IPO Equity

Scholar Rock, Inc., a biotechnology company, discovers and develops a class of biologic therapies that selectively target dysregulated growth factors in the disease microenvironment by modulating supracellular activation. The company’s drug discovery programs target growth factors which are present in the microenvironments of significant diseases, including fibrosis, musculoskeletal diseases, immuno-oncology, and autoimmune diseases. Its lead products include SRK-015, a selective and local inhibitor of latent myostatin activation for the treatment of primary myopathies. The company was incorporated in 2012 and is based in Cambridge, Massachusetts.

Scholar Rock Holding Corporation

Omega Therapeutics raised $126000000 on 2021-03-30 in Series C

Omega Therapeutics, Inc. develops genomic medicines to cure diseases. The company focuses on precision tuning to activate the human genome’s native capacity to treat and cure diseases. It engages in designing, engineering, and manufacturing Epigenomic Controllers to target the GenomStats for the cell types of interest, with the ability to downregulate or upregulate genomic activity for therapeutic effect. Omega Therapeutics, Inc. was formerly known as VL42, Inc. and changed its name to Omega Therapeutics, Inc. in August 2017. The company was founded in 2016 and is based in Cambridge, Massachusetts.

Omega

EQRx raised $1200000000 on 2021-12-17 in Post-IPO Equity

EQRx operates as a biotechnology company, focused on re-engineering the process from drug discovery to patient delivery with the goal of offering a market-based solution for the rising cost of medicines. By bringing together stakeholders from across the healthcare system and utilizing the latest advances in science and technology, the company seeks to discover, develop and deliver high-quality, patent-protected medicines more efficiently and cost-effectively than ever before.

The company was founded in 2019 and is based in Cambridge, Massachusetts, United States.

EQRx

Cyclerion Therapeutics raised $18000000 on 2021-06-04 in Post-IPO Equity

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.

Cyclerion Therapeutics

Cava Group raised $190000000 on 2021-04-27 in Series F

Cava Group, Inc. owns and operates a chain of Greek and Mediterranean restaurants. It offers salads, dips, spreads, toppings, and dressings. The company has strategic partnerships with Garden School Foundation, Sow Much Good, Urban Roots, and Future Chefs. Cava Group, Inc. was founded in 2006 and is headquartered in Washington, District Of Columbia.

Cava Group, Inc.

ElevateBio raised $525000000 on 2021-03-15 in Series C

ElevateBio is a operator of a portfolio of cell and gene therapy companies intended to develop, manufacture and commercialize life-transforming medicines. The company creates a portfolio through partnerships with the world's most innovative scientists and inventors as well as it created a centralized facility that integrates all the elements that translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.

ElevateBio

Repertoire Immune Medicines raised $189000000 on 2021-04-13 in Series B

Repertoire Immune Medicines is a clinical stage biotechnology company working to unleash the human immune system to prevent, treat or cure cancer, autoimmune conditions and infectious diseases. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.

Repertoire Immune Medicines, Inc.

Wiloki raised $1198234 on 2021-04-16 in Venture Round

Wiloki is an innovative and motivating platform for children and teenagers aged 7 to 14. The personalized educational tool, enriched with artificial intelligence, intends to develop in Europe and enrich its educational content offer.

Wiloki

Septerna raised $100000000 on 2022-01-27 in Series A

Septerna

Moderna Therapeutics raised $450000000 on 2015-01-05 in Series E

Moderna Therapeutics is a biotechnology company that develops messenger RNA therapeutics. Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease. It provides in vivo drug modality that produces human proteins or antibodies inside patient cells. 

Moderna Therapeutics also develops various patent applications with various claims ranging from novel nucleotide chemistries to specific drug compositions. It focuses on disease areas, such as inherited genetic disorders, hemophilia, and blood factors, and oncology. 

Moderna Therapeutics in 2010 and is headquartered in Cambridge in Massachusetts. It has strategic option agreements with AstraZeneca and Alexion Pharmaceuticals and strategic collaborations with Karolinska Institutet, Institut Pasteur, Karolinska University Hospital, and Merck.

Moderna Therapeutics

Fog Pharmaceuticals raised $23271035 on 2021-01-04 in Venture Round

FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer.

FogPharma is laser-focused and unstoppable in its mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.

Fog Pharmaceuticals, Inc.

Metacrine raised $65000000 on 2018-06-06 in Series C

Metacrine is a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal (GI) diseases. The most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. Beyond the FXR program, a pipeline of novel drug candidates against other drug targets is being explored by taking advantage of internal drug discovery and development capabilities.

Metacrine

MarkaVIP raised $5000000 on 2011-12-06 in Series A

Markavıp is an exclusive, invitation-only online shopping community focused on the Middle Eastern market. The website specializes in offering flash sales to its customers.

Markavıp was founded by Ahmed Alkhatib, who previously spent 12 years in Silicon Valley working in the e-commerce industry. The website enjoys memberships from over 3 million exclusive members across eight Arabic speaking countries including Jordan, Saudi Arabia, UAE, Qatar, Kuwait, Lebanon, Bahrain, and Oman.

MarkaVIP

Lycia Therapeutics raised $70000000 on 2021-09-09 in Series B

Lycia Therapeutics is a biotechnology company that focuses on developing technology that utilizes lysosome-targeting chimeras. The company was founded by Carolyn R. Bertozzi in 2019 and is based in San Diego, California, USA.

Lycia Therapeutics

Jahia raised $22500000 on 2015-02-10 in Venture Round

Jahia is a leading open source User eXperience Platform (UXP) vendor, relentlessly working at transforming a silo industry into a user-driven one, beyond technology constraints. Each solution provided by Jahia stems from Jahia’s Digital Industrialization vision: to streamline Enterprise digital projects across all channels and truly accelerate corporate-wide deployments, by bridging the IT/Marketing lifecycle gap. 

Founded in 2002 and headquartered in Geneva, Switzerland, Jahia Solutions Group has its North American headquarters in Washington DC, with offices in Chicago, Toronto and throughout Europe. Jahia counts hundreds of global brands and governmental organizations among its loyal customers, in more than 20 countries across the globe. Early 2015, the company announced its first round of funding from Invus for €20 millions

Jahia

Laronde raised $440000000 on 2021-08-30 in Series B